从肝细胞癌风险角度谈HBeAg阳性患者的治疗适应证

摘要/Abstract

摘要： 2024年初,来自韩国的研究团队发表了一项历史性队列研究,探索无肝硬化的HBeAg阳性慢性乙型肝炎成年患者抗病毒治疗启动前HBV DNA水平与治疗期间肝细胞癌风险的相关性,引发学界广泛讨论。HBeAg阳性患者的治疗适应证历来都是争论的焦点,我国及国际最新指南倾向于依据乙型肝炎肝硬化或肝细胞癌家族史、年龄、肝脏病变和乙型肝炎病毒相关肝外表现等进行治疗决策,淡化对自然史的依赖,以“应治尽治”和“全员治疗”的理念尽可能扩大乙肝病毒感染者治疗人群。

关键词: 慢性乙型肝炎, 乙型肝炎e抗原, 肝细胞癌, 治疗

赵西太, 聂青和. 从肝细胞癌风险角度谈HBeAg阳性患者的治疗适应证[J]. 肝脏, 2025, 30(12): 1591-1594.

/ 推荐

参考文献

[1] The Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study[J]. Lancet Gastroenterol Hepatol, 2023,8(10):879-907.
[2] World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries[M]. Geneva: World Health Organization, 2024.1009624088.
[3] 中国医师协会感染科医师分会,国家感染性疾病临床医学研究中心. 乙型肝炎全人群管理专家共识(2023)[J]. 中华临床感染病杂志, 2024,17(1):1-13.
[4] 中华医学会感染病学分会,中华医学会肝病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 实用肝脏病杂志, 2023,26(03):457-478.
[5] 庄辉. 扩大慢性乙型肝炎治疗[J]. 临床肝胆病杂志, 2023,39(1):10.
[6] Choi W M, Yip T C, Kim W R, et al. Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: a multinational cohort study of HBeAg-positive patients[J]. Hepatology, 2024,80(2):428-439.
[7] Terrault N A, Lok A, Mcmahon B J, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018,67(4):1560-1599.
[8] Liver E A F T. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017,67(2):370-398.
[9] Feld J, Janssen H L, Abbas Z, et al. World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015[J]. J Clin Gastroenterol, 2016,50(9):691-703.
[10] Sarin S K, Kumar M, Lau G K, et al. Asian-Pacific Clinical Practice Guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int, 2016,10(1):1-98.
[11] Liu M, Zhao T, Zhang J, et al. Estimating the key outcomes and hepatocellular carcinoma risk in patients in immune-tolerant phase of chronic hepatitis B virus infection:a systematic review and meta-analysis[J]. Rev Med Virol, 2024,34(4):e2570.
[12] Huang J, Liu Y, Liu Y. Antiviral therapy in hepatitis B virus-infected with immune-tolerant: a meta-analysis[J]. Gastroenterol Hepatol, 2023,46(4):309-318.
[13] Yoo J J, Park S Y, Moon J E, et al. Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase[J]. Clin Mol Hepatol, 2023,29(2):482-495.
[14] World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection[M]. Geneva:World Health Organization, 2024.1009623319.
[15] Papatheodoridis G V, Voulgaris T, Papatheodoridi M, et al. Risk scores for hepatocellular carcinoma in chronic hepatitis B: a promise for precision medicine[J]. Hepatology, 2020,72(6):2197-2205.
[16] Choi W M, Kim G A, Choi J, et al. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B[J]. J Clin Invest, 2022,132(10).
[17] Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol, 2020,73(6):1368-1378.
[18] Broquetas T, Carrión J A. Past, present, and future of long-term treatment for hepatitis B virus[J]. World J Gastroenterol, 2023,29(25):3964-3983.
[19] Papatheodoridis G V, Sypsa V, Dalekos G N, et al. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B[J]. J Hepatol, 2020,72(6):1088-1096.
[20] 中华医学会肝病学分会肝炎学组,中华肝脏病杂志编辑委员会. 加速消除乙型肝炎病毒感染:扩大预防和治疗专家建议[J]. 中华肝脏病杂志, 2024,32(6):497-503.
[21] 庄辉. 慢性乙型肝炎:从“只治”到“全治”[J]. 中华肝脏病杂志, 2024,32(5):389-393.
[22] 赵西太,聂青和. 重视慢性乙型肝炎临床管理中的低病毒血症[J]. 中西医结合肝病杂志, 2021,31(07):661-665.
[23] 中华医学会感染病学分会,中华医学会肝病学分会,Association Chinese Medical. 慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 临床肝胆病杂志, 2019,35(8).